Mucopolysaccharidosis IIIB
Conditions
Brief summary
This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.
Interventions
DRUGJR-446
IV infusion
Sponsors
JCR Pharmaceuticals Co., Ltd.
MEDIPAL HOLDINGS CORPORATION
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 5 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with confirmed MPS IIIB with a phenotype of MPS IIIB that is not classified as slowly progressive (i.e., not attenuated). 2. A chronological age \<6 years. 3. Ability to complete and achieve a Standard score ≥55, using either Bailey Scale of Infant Development-4 (BSID-4) Cognitive domain or Kaufman Assessment Battery for Children-II (KABC-II) Non-Verbal Index, whichever tool is most appropriate for the participant's chronological age.
Exclusion criteria
1. Contraindication for lumbar puncture or MRI. 2. A participant who has a medical condition or extenuating circumstance that, in the opinion of the principal investigator or sub-investigator, might compromise the participant's ability to comply with protocol requirements, the participant's well-being or safety, or the interpretability of the participant's clinical data. 3. A participant who has received any other investigational drug product (including but not limited to, tralesinidase alfa enzyme replacement therapy \[TA-ERT\], Genistein, KINERET \[anakinra\], ambroxol, miglustat) within 4 months (or 5 half-lives, whichever is longer) before the time of providing informed consent. 4. A participant who has received gene therapy treatment or hematopoietic stem cell transplantation (HSCT) with successful engraftment. 5. Serious drug allergy or hypersensitivity to any components of JR-446 or medications likely prescribed during the trial. 6. A participant has a history of bleeding disorder or current use of medications that, in the opinion of the investigator, place them at risk of bleeding following lumbar puncture. 7. A patient with recurrent epileptic seizures not adequately controlled with anti-seizure medication, and which, in the clinical judgment of the principal investigator, would preclude safe participation in the trial. 8. Serology consistent with human immunodeficiency virus (HIV) exposure or consistent with active hepatitis B (HepB) or hepatitis C (HepC) infection. 9. A participant/family, who, in the opinion of the investigator, may not be able to comply with protocol requirements and cooperate fully with the trial assessments, procedures, and scheduling for JR-446 IMP dose administrations. 10. Study participants for whom informed consent is unable to be provided by a parent or legal guardian; or when applicable for a study participant who is unable to provide assent with respect to study participation in conjunction with parental or legal guardian consent for participation on study. The above information is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To establish the safety and tolerability of JR-446 in MPS IIIB patients following repeated dose administration | Up to 1 year (multiple visits) | Incidence and severity of treatment-emergent adverse events; Incidence and severity of infusion-associated reactions; Incidence of clinically significant changes/abnormalities in safety laboratory tests, vital signs, and electrocardiogram. |
Secondary
| Measure | Time frame |
|---|---|
| Change From Baseline in Cerebrospinal Fluid Heparan Sulfate Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Absolute Change From Baseline in Serum Heparan Sulfate Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Percent Change From Baseline in Serum Heparan Sulfate Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Absolute Change From Baseline in Urine Heparan Sulfate Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Percent Change From Baseline in Urine Heparan Sulfate Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Absolute Change From Baseline in Serum Neurofilament Light Chain Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Percent Change From Baseline in Serum Neurofilament Light Chain Concentration | Through Week 53 (up to 1 year; multiple visits) |
| Change in Cognitive Function Assessments From Baseline | Through Week 53 (up to 1 year) |
| Change in Brain MRIs From Baseline | Through Week 53 (up to 1 year) |
| Change in Height Standard Deviation Score (SDS) From Baseline (using WHO child growth standards) | Through Week 53 (up to 1 year) |
| Change in Weight SDS From Baseline (using WHO child growth standards) | Through Week 53 (up to 1 year) |
| Change in Body Mass Index (BMI) SDS From Baseline (using WHO child growth standards) | Through Week 53 (up to 1 year) |
Countries
Germany, United Kingdom, United States
Contacts
CONTACTJCR Pharmaceuticals Co., Ltd.
Outcome results
None listed